Zenas BioPharma, Inc. (ZBIO) Form SCHEDULE 13D/A — Aug 19, 2026
Enavate Sciences GP, LLC and Zebra Aggregator, LP sold 673,755 shares of Zenas BioPharma (ZBIO) common stock on August 19, 2026 in an open market sale at a weighted average price of $31.44 per share, within a $31.05 to $32.00 range. Following the sale, the Reporting Persons beneficially own 3,245,404 shares, or 4.98% of the 65,176,723 shares outstanding as of July 31, 2026, and ceased to be beneficial owners of more than five percent of the common stock on August 19, 2026.
Key figures
- Shares Outstanding
- 65176723
- Sale Date
- 2026-08-19
- Shares Sold
- 673755
- Sale Price Low Usd
- 31.05
- Sale Price High Usd
- 32
- Derived Prior Percent
- approximately 6.0% (derived: 3,919,159 shares of 65,176,723 outstanding)
- Implied Sale Value Usd
- approximately $21.2 million (derived: 673,755 shares x $31.44 weighted average price)
- Shares Owned Post Sale
- 3245404
- Percent Owned Post Sale
- 4.98% (rounded down to 4.9% on EDGAR cover due to field limits)
- Five Percent Ceased Date
- 2026-08-19
- Shares Outstanding As Of
- 2026-07-31 per 10-Q filed August 13, 2026
- Sale Weighted Avg Price Usd
- 31.44
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.